Navigation Links
RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders
Date:1/14/2014

WESTBOROUGH, Mass., Jan. 14, 2014 /PRNewswire/ -- RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that it received the Notice of Allowance from the United States Patent and Trademark Office on its unique self-delivering RNAi compounds (sd-rxRNA®), for the treatment of fibrosis. The patent covers the use of sd-rxRNAs targeting CTGF, including RXI-109, for the treatment of fibrotic disorders. The patent, once issued, will be scheduled to expire in 2029.

"This notice of allowance from the USPTO is of high importance for RXi's Intellectual Property position in the RNAi field, and more specifically in the space of skin and organ fibrosis," said Dr. Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals. He added that, "Our sd-rxRNA compound, RXI-109 targeting CTGF, has already demonstrated excellent safety results in our Phase 1 trials and has confirmed the mechanism of action of this self-delivering RNAi in humans in a dose dependent manner. This patent enhances our ability to broadly protect our proprietary technology, including our anti-fibrotic compounds, reinforcing the potential for future commercial and business development opportunities."

About RXI-109

RXi Pharmaceuticals' first clinical program involves RXI‑109, a self-delivering RNAi compound (sd‑rxRNA®) developed for the reduction of dermal scarring. RXI‑109 is designed to reduce the expression of CTGF, a critical regulator of biological pathways involved in fibrosis, including scar formation in the skin. The first clinical trials with RXI‑109 showed excellent safety and tolerability with ascending single and multiple doses, as well as dose dependent effects on the Connective Tissue Growth Factor protein an
'/>"/>

SOURCE RXi Pharmaceuticals Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
3. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
4. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
5. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
6. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
7. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
8. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
9. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
10. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
11. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014 /PRNewswire-iReach/ -- DeepResearchReports.com ... China Acetic Acid Industry" and "2014 Deep Research ... reports to its research database. Photo ... Deep Research Report on Global and China Acetic ... report on China and ...
(Date:9/18/2014)... 18, 2014  Health Enhancement Products, Inc. (OTCQB: HEPI), a ... bioactive compounds and metabolic processes, is pleased to announce the ... directors. Ms. Nola E. Masterson , a ... board effective September 17, 2014. "We,re very ... our board," states Andrew Dahl , President and CEO. ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 Texas ... John Sharp, Texas A&M Health Science Center CEO ... Department of Health and Human Services (HHS), State ... a national pandemic influenza vaccine manufacturing facility in ... an anchor for the Texas A&M Biocorridor – ...
(Date:9/18/2014)... Research and Markets has announced ... Cell Industry Report, 2014-2017" report to their offering. ... that can differentiate into specialized cells and can divide ... therapy can be applied to treatment of cardiovascular diseases, ... diseases, damage or lesion of liver, kidney and other ...
Breaking Biology Technology:Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 2Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 3Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 4Health Enhancement Announces New Board Member In Advance Of Annual Shareholder Meeting 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 3Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 4Global and Chinese Stem Cell Industry Report, 2014-2017 2Global and Chinese Stem Cell Industry Report, 2014-2017 3
... Therapeutics, Inc., a,privately held biopharmaceutical company, announced today ... will present a corporate,overview at the JMP Securities ... 7 at 9 a.m. ET at the Le ... Horizon Therapeutics, Inc. is a late-stage biopharmaceutical company,focused ...
... 1 Halozyme Therapeutics, Inc.,(Nasdaq: HALO ), ... extracellular matrix, today announced that it will,host a ... 12:15 p.m. EDT. A,webcast of the presentations will ... PRESENTATIONS, -- Strategic Company Overview, Jonathan Lim, ...
... - OncoGenex,Pharmaceuticals, Inc (NASDAQ: OGXI ) will ... on October 2 at 4:30 pm ET in ... City. OncoGenex, President and,Chief Executive Officer, Scott Cormack, ... a discussion of the Company,s lead cancer drug,candidate ...
Cached Biology Technology:Halozyme Therapeutics to Host Research Day for Investors and Analysts 2
(Date:9/18/2014)... the ultimate form of camouflage: you don,t just blend ... is not as uncommon as you might think. Kathryn ... explains that the larval life stages of many marine ... the anatomy that most creatures cannot make transparent. Feller ... shield each individual eye unit with an opaque pigment ...
(Date:9/18/2014)... Clownfish spend their entire lives nestling in the protective ... as babies they sometimes travel hundreds of kilometres across ... by reef fish has been predicted, this is the ... between distant populations has been observed. , Dr Steve ... at the University of Exeter, and colleagues from the ...
(Date:9/17/2014)... were instrumental in the creation of the Santa Ana ... the fire threat potential of the powerful, hot, dry ... an inferno. The index was introduced Sept. 17 by ... San Diego Gas and Electric. , The index includes ... will be used to help fire agencies and other ...
Breaking Biology News(10 mins):Transparent larvae hide opaque eyes behind reflections 2Expedition finds Nemo can travel great distances to connect populations 2Expedition finds Nemo can travel great distances to connect populations 3UCLA scientists play key role in developing new Santa Ana Wildfire Threat Index 2
... (UW) researchers have gathered evidence that dangerous plaques in ... are fat-laden rough spots in the otherwise smooth walls ... of it, a process known as plaque hemorrhage. The ... flow of oxygen-rich blood is restricted, a heart attack, ...
... A Brazilian scorpion has provided researchers at North ... venom,s effects on the ability of certain cells to ... understanding diseases like pancreatitis or in targeted drug delivery. ... an inflammation of the pancreas. ECU microbiologist Dr. Paul ...
... Science Foundation has bestowed a Faculty Early Career Development ... molecular biologist and geneticist whose work since she joined ... her passion for research and her commitment to training ... Award is an exceptional recognition of exceptional qualities in ...
Cached Biology News:Dangerous plaques in blood vessels rupture by overproducing protein-busting enzymes 2Dangerous plaques in blood vessels rupture by overproducing protein-busting enzymes 3Dangerous plaques in blood vessels rupture by overproducing protein-busting enzymes 4Scorpion venom provides clues to cause, treatment of pancreatitis 2FSU biologist wins $1M Early Career Award from National Science Foundation 2FSU biologist wins $1M Early Career Award from National Science Foundation 3
Human peripheral blood eosinophils, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Granulocytes...
Human peripheral blood PBMCs, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood PBMC and T Cells...
Cord blood endothelial progenitor cells, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood Progenitor Cells...
Human plasmacytoid dendritic cells, BDCA-4+, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Dendritic Cells and EPCs...
Biology Products: